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Abstract
S aureus internalized by bone cells and shielded from the immune system provides a reservoir of
bacteria in recurring osteomyelitis. Its targeting by the antibiotic therapy may thus be more
relevant for treating chronic bone infection than eliminating only the pathogens colonizing the
bone matrix. Assessed was the combined osteogenic and antibacterial effect of clindamycin-
loaded calcium phosphate nanoparticles of different monophasic compositions on co-cultures
comprising osteoblasts infected with S aureus. Antibiotic-carrying particles were internalized by
osteoblasts and minimized the concentration of intracellular bacteria. In vitro treatments of the
infected cells, however, could not prevent cell necrosis due to the formation of toxic byproducts of
the degradation of the bacterium. Antibiotic-loaded particles had a positive morphological effect
on osteoblasts per se, without reducing their viability, alongside stimulating upregulation of
expression of different bone growth markers in infected osteoblasts to a higher degree than
achieved during the treatment with antibiotic only.
Keywords
Calcium Phosphate; Controlled Drug Delivery; Nanoparticles; Osteogenesis; Osteomyelitis;
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Introduction
The continuously aging population on Earth insinuates a rise in the number of bone diseases,
including the infectious ones, such as osteomyelitis [1]. The incidence of osteomyelitis in
the US is 1 – 2 %, but the disease is far more prevalent in the developing countries as well as
among particular patient populations: approximately 1 in 5000 among children, 1 in 1000
among neonates, 1 in 250 among sickle cell patients, 1 in 7 among diabetics and 1 in 3
among patients with punctured foot [2 – 5]. Since bone tissues are relatively well shielded
from the external pathogens that may cause the infection, osteomyelitis is particularly
common among the orthopedically postoperative and posttraumatic patients [6]. Conversely,
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however, this means that, once infected, bone tissues are difficult to target by conventional
antibiotic therapies. The traditional approach to the treatment of osteomyelitis involves (a)
repetitive administration of antibiotics, typically by intravenous or oral means for up to six
weeks, frequently followed by a 6-month course of oral antibiotics in the case of chronic
infection, and (b) surgical removal of the osteonecrotic portion of bone malformed due to
disease so as to prevent chronically recurrent infection due to sequestra inaccessible to
immune cells or antibiotics [7]. The main downsides of this conventional type of treatment
include: (a) systemic distribution of the antibiotic throughout the organism and the
corresponding side effects [8]; (b) its lower concentration in the target area, potentially
promoting bacterial resistance to the therapy; (c) the necessity of physical removal of the
necrotic bone and the installment of lasting prostheses or implants; and (d) cost-
ineffectiveness, as a daily dose of orally or intravenously administered antibiotics ranges in
excess of $100 per patient. Incentives thus exist to develop an antibiotic delivery system for
(a) sustained therapeutic concentration of the drug in the target zone and (b) the ability to
enhance the remineralization of the tissue lost to disease.
Although osteomyelitis can be caused by a variety of pathogens, most of which reside in
healthy oral flora, S aureus stands for the main causative agent thereof [9]. S aureus, which
is found in healthy oral and nasal flora, has the ability to penetrate endothelial, epithelial and
osteoblastic cells, and thrive in the intracellular environment where it could be less
susceptible to antibiotic-related destruction [10 – 12]. S aureus internalized by the cells and
shielded from the host immune system is thought to provide a reservoir of bacteria in
recurring osteomyelitis and its targeting by the antibiotic may thus be more relevant for
treating chronic bone infection than eliminating merely pathogens colonizing the bone
matrix [13]. Another rationale behind the usage of particulate carriers for intracellular
delivery of antibiotics comes from the fact that many colonies create an acidic milieu that
can drastically reduce the potency of antibiotic in its pure form [14]. Our previous studies
have shown that calcium phosphates (CAPs) of various stoichiometries could present a
viable candidate for drug delivery carriers for tunable release of antibiotics in the treatment
of osteomyelitis [15]. Our earlier report confirming the antibacterial effectiveness against S
aureus in both suspended and surface-bound forms [16] is supplemented hereby with the
assessment of the bactericidal performance of antibiotic-loaded CAP particles with respect
to osteoblastic cells infected with the given bacterium as well as of their osteoconductive
and osteogenic potentials.
The choice for drug delivery agents utilized in this work has been derived from the
incentives to come up with a biocompatible, biodegradable and osteogenic material with
tunable degradation and drug release kinetics. Local and sustained delivery of gentamicin
has been clinically achieved since the mid-1970s by means of surgical implantation of
millimetric polymethyl methacrylate beads [17], which still present the gold standard in
local antibiotic therapy for the treatment of osteomyelitis [18]. Their non-osteogenic and
non-biodegradable nature that requires secondary surgical procedure for their removal from
the patient has, however, made it impossible to promote conditions for spontaneous
regeneration of diseased bone [19]. The premise of this study stems from a belief that a
compositional similarity between the ceramic component of bone and artificial calcium
phosphates makes the latter an ideal candidate for the carriers of locally deliverable
antibiotics in the treatment of osteomyelitis. In the past and with respect to the broad
spectrum of phase compositions of CAPs, only two CAP phases were utilized for the sake of
controlling the biodegradation rate of monophasic or biphasic mixtures thereof:
hydroxyapatite (HAP) and tricalcium phosphate. In particular, the approach to bone
regeneration by means of surgical implantation of synthetic CAPs has paradigmatically
relied on HAP, the phase already present in bone. However, we believe that since
osteoblasts eventually build new hard tissues from its ionic and organic ingredients, more
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resorbable phases, including dicalcium phosphate (DCPA), shown in our former work to
boost gene expression that promotes in vitro bone growth more than other, less soluble CAP
phases, should be paid more attention to. In this study, we have focused on three different
phases of CAP that cover a broad range of solubilities, from pKsp = 7 (DCPA) to pKsp = 20–
25 (amorphous CAP; ACP) to pKsp = 117 (HAP). Our previous work has shown that
sustained release of drugs could be made directly relatable to the degradation rate of CAP
carriers [20]. In theory, by combining these different CAP phases in various proportions,
drug release profiles could be tailored to the therapeutic occasion. By varying the phase
composition of the particles, an optimal balance between bioactivity and biodegradability
could be achieved, so as to provide an osteoconductive surface for osteoblasts to adhere onto
and match the rather slow rate of new bone formation, while at the same time ensuring
sufficient degradation and drug release rates to eradicate the pathological source of infection
and provide ionic species that will serve as ingredients of the newly forming bony tissues.
Finally, it should be noted that methodologically wedded in this study are molecular
biology, classical bacteriology and materials science, all under one umbrella. It is a necessity
today, when research at the frontier is, as a rule, of interdisciplinary nature, to combine
methodologies that have traditionally belonged to separate fields. To the same degree as
they are challenging for the interpreters and the inquirers alike, these phenomena lying at the
boundary between different fields carry a potential for the discovery of new and more
sophisticated technological and therapeutic tools.
Materials and methods
Synthesis and characterization of clindamycin-containing CAP nanopowders
Synthesis of different monophasic nanoparticulate powders of CAP and their loading with
clindamycin phosphate (CL), a common antibiotic of choice in the treatment of acute
ostemyelitis [21], was described in a previous report [16]. Briefly, an aqueous solution of
NH4H2PO4 was admixed to an identical volume of an aqueous solution of Ca(NO3)2 at
different pHs, ionic concentrations and rates, depending on the intended phase composition
to be obtained. Table 1 summarizes these parameters and includes other physical properties
of these powders. For the formation of all powders except ACP, the precipitate was
additionally brought to the boiling point, then immediately cooled down at room
temperature, aged for 24 h, washed with distilled water, centrifuged, and dried in vacuum (p
= −20 mm Hg) at room temperature. In this method, CL dissolved in water was introduced
to CAP suspensions immediately after their cooling down to room temperature. To ensure
that CL was stably confined in the porous pockets of the powder and released at a sustained
rate, CAP particles with CL physisorbed on them were dried in vacuum. Compact blocks
were formed thereby, protecting the bulk of the drug from immediate contact with the
solvent and premature release. Cobalt-doped HAP as the negative control for osteoblastic
compatibility tests was prepared with 5 wt% of Co according to a previously reported
procedure [22]. The phase composition of the particles was analyzed on a Bruker AXS D4
Endeavour X-ray diffractometer using CuKα = 1.5418 Å as the wavelength of the radiation
source. The step size was 0.02 °, with 2 s of the sample irradiation time per step. The
average size of the crystallites was determined using a structural refinement approach
(Topas 2.0) based on the previously identified crystal structure (PCPDFWIN & Eva). The
size distribution profiles and morphology of the powders were analyzed on a Hitachi
S-4300SE/N scanning electron microscope (SEM). Mac Biophotonics ImageJ software was
used to measure the average particle size from the obtained electron micrographs. High-
resolution transmission electron microscopy (HR-TEM) analysis of CAP nanopowders was
performed on a FEI monochromated F20 UT Tecnai HR-TEM under the electron
acceleration voltage of 200 kV. Raman spectra were taken on a Renishaw inVia Reflex
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Raman microscope, in the high throughput mode, using low laser power of 2 – 5 mW, λ =
532 nm, the groove grating of 2400, and a 50x objective.
Cell culture
Mouse calvarial preosteoblastic cell line, MC3T3-E1 subclone 4, was purchased from
American Tissue Culture Collection (ATCC, Rockville, MD) and cultured in Alpha
Minimum Essential Medium (α-MEM; Gibco) supplemented with 10% fetal bovine serum
(FBS, Invitrogen) and no ascorbic acid (AA). The medium was replaced every 48 h, and the
cultures were incubated at 37 °C in a humidified atmosphere containing 5% CO2. Every 7
days, the cells were detached from the surface of the 75 cm2 cell culture flask (Greiner Bio-
One) using 0.25 wt% trypsin, washed, centrifuged (1000 rpm x 3 min), resuspended in 10 ml
α-MEM and subcultured in 1:7 volume ratio. Cell passages 8 – 16 were used for the
experiments reported hereby. The cultures were regularly examined under an optical
microscope to monitor growth and possible contamination.
Differentiation and invasion assay
Cells were seeded on glass cover slips placed in 24 well plates and 500 μl of α-MEM
supplemented with 10% fetal bovine serum (FBS, Invitrogen) and no AA at the density of 6
× 104 cells per well. After 5 days of incubation, nearly confluent cells were treated with α-
MEM containing 50 μg/ml AA as the mineralization inductor. After 2 days, the media were
aspirated and the cells were washed with PBS and had antibiotic-free RPMI-1640 medium
buffered with 25 mM HEPES and containing sodium bicarbonate added to them. Previously,
a single colony of Staphylococcus aureus (ATCC 25923) cultured on a blood agar plate over
48 hours was stabbed with a pipette tip and added to 5 ml of 37 mg/ml brain heart infusion
(BHI) broth and kept on an incubator shaker (Innova 44) overnight at 37 °C and 225 rpm.
To fluorescently label the bacteria, fluorescein isothiocyanate (FITC) was added to the
bacterial broth 4 h into the inoculation to the concentration of 100 μg/ml, following a
modified previously described protocol [24]. Five microliters of this freshly inoculated broth
were added to 500 μl of 25 mM of NaCO3-containing HEPES media previously added to the
cells. The given bacterial amount corresponded to circa 6.25 × 107 colony forming units,
according to the results of comparison of optical transparency with McFarland standards
prepared by mixing 1 wt% BaCl2 solution and 1 wt% H2SO4 in the volume ratio of 1:200,
respectively. To induce intracellular infection, cells were incubated for 2 h at 37 °C, as in
accordance with the previously reported invasion time scale [25 – 27], in a CO2-free
incubator, after which they were washed once with PBS, replenished with fresh antibiotic-
free RPMI-1640 media and had 2 mg/cm2 of CAP particles loaded with CL (Tokyo
Chemical Industry) added to them. The amount of the particles added to each well was
normalized to the surface area rather than to cell culture medium volume because particles
initially sediment to the bottom of the wells where cells are exclusively found. Normalized
to the cell culture medium volume, the amount of CL-loaded particles used to treat the
infected cells with equaled 4 mg/ml. Negative controls (C−) were uninfected and positive
controls (C+) were infected but not treated with either CAP particles or CL. When treated
with CL only, the infected cells were given the amount of antibiotic that equaled the amount
of CL-loaded CAP particles that other experimental groups were treated with. Subsequent
incubation in a CO2-free environment took place over different periods of time, ranging
from 1 to 48 h, after which a portion of the samples was analyzed for the amount of
mitochondrial dehydrogenases, indicative of the metabolic activity of the cells, using MTT
(3-[4, 5-dimethylthiazol-2-yl]-2, 5-diphenyl tetrazolium bromide) in vitro toxicological
assay (Sigma). Another portion of the samples was stained for osteoblastic cell nucleus and
cytoskeletal f-actin using a previously described protocol [16]. All the experiments were
done in triplicates and the fluorescence of the FITC-tagged bacterium was measured under
identical excitations from four randomly selected images in each sample. The subsequent
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average pixel intensity analysis was performed using ImageJ and NIS Elements software.
Both single-plane and volume-rendered z-stack images (12 – 15 of them) spaced by 1 μm
were also collected. The third portion of the samples was lysed with 0.1 wt% Tween-20 for
5–10 min. To minimize lysis of intracellular and extracellular bacterial cell walls during
permeabilization, the effect known to occur when Triton-X, the standard permeabilization
agent, is used [28], the latter was substituted with a milder, nonionic surfactant, Tween-20
known to be non-injurious to fastidious microbial pathogens [29]. One part of the lysed
samples was mixed with BHI broths in 1:10 ratio and incubated for 4 – 24 h at 37 °C and
225 rpm. After the given period of time, the broths were analyzed for optical density at 600
nm on a UV/Vis spectrophotometric microplate reader (Molecular Devices: Spectra Max
190). Two microliters of the lysates were also spread on top of sheep blood agar plates,
incubated overnight at 37 °C and counted for the number of colonies the following day.
Invasion assays were also carried out using mutants of S aureus potentially resistant to the
antibiotic. For that purpose, differentiated MC3T3-E1 cells were co-cultured with the
bacterium and 2 mg/cm2 CL for 48 h using the aforementioned procedure, lysed, streaked on
an agar plate and incubated at 37 °C overnight. A single colony was picked off the plate and
added to a fresh BHI broth. The latter was inoculated overnight and a portion of it was used
to infect differentiated MC3T3-E1 cells via the aforementioned procedure.
For the purpose of qPCR analysis, MC3T3-E1 cells were seeded in 96 well plates and 100 μl
of α-MEM supplemented with 10% fetal bovine serum (FBS, Invitrogen) and no AA at the
density of 2 × 104 cells per well. After 3 days of incubation, the medium was replaced with
α-MEM containing 50 μg/ml AA as the mineralization inductor. After a 24 h incubation, the
cells had 100 μl of antibiotic-free RPMI-1640 medium buffered with 25 mM HEPES and
containing sodium bicarbonate added to them, altogether with 2 μl of S aureus in a freshly
inoculated BHI broth (equivalent to circa 3 × 107 colony forming units). After 2 h of the
invasion time, the medium was refreshed and 1 mg of HAP, with and without the antibiotic,
including antibiotic alone (1 mg), were added to the co-culture and incubated for 24 h. After
the given time, cell lysis, reverse transcription (Bio-Rad) and qPCR (Applied Biosystems,
StepONEPlus) were performed using the Fast SYBR Green Cells-to-CT kit (Ambion) in
accordance with the manufacturer’s instructions. Each experiment was done in triplicates
and each experimental replica was analyzed for mRNA expression in triplicates too (n = 3 ×
3). The expressions of one housekeeping gene, β-actin (ACTB), and five osteogenic markers,
mouse type I procollagen (Col I), osteocalcin (BGLAP), alkaline phosphatase (ALP),
osteopontin (BSP-1) and Runx2, were analyzed. Table 2 shows the primer pair sequences
used [30 – 32]. The real-time PCR results were analyzed using the ΔΔCt method [33] and all
the data were normalized to ACTB expression levels. Comparison in the mRNA transcript
levels of ACTB itself was carried out by normalizing the cycle number (Ct) for each sample
to fit the Ct range between that for the uninfected, negative control (~ 21) and the maximal
cycle number on the given device (~ 40), approximated to correspond to zero cell viability.
Results and discussion
SEM images of CL-loaded HAP powders shown in Fig. 1a–b demonstrate their
nanoparticulate nature, with particles being spherical in shape and with sizes in the
nanoparticle range (< 100 nm). The same nanosized and spherical nature was observed for
the other two CAP phases: DCPA (Fig. 1d) and ACP (Fig. 1e). XRD patterns of three
different CAP phases with different solubilities utilized in this study - DCPA, ACP and HAP
– are displayed in Fig. 2a. Naturally, the average particle sizes were bigger than the average
crystallite sizes for each of the powders: 84 vs. 12 nm for HAP, 74 vs. 33 nm for DCPA, and
62 vs. less than 5 Å for ACP (Table 1). The amount of CL captured by each powder per unit
weight was inversely proportional to the average particle size, being highest, in excess of 5
wt%, for ACP and smallest, less than 1 wt%, for DCPA [15]. As could be seen from the
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portion of Raman spectrum of HAP shown in Fig. 2b, the characteristic non-degenerate
symmetric stretch of the phosphate tetrahedron was detected at 961 cm−1, while the
corresponding stretch of the carbonate ion was detected at 1075 cm−1, suggesting a particle
substitution of PO43− ions of HAP with CO32−, the product of which is the so-called B-type
carbonated HAP. Unlike the A-type which typically forms upon annealing at elevated
temperatures [34] and wherein CO32− occupy the place of OH− groups in the unit cell of
HAP, exhibiting the blue shift of ν1(CO3) to ~ 1100 cm−1, the B-type is the typical product
of precipitation of HAP from aqueous solutions under atmospheric conditions. Carbonate
ions are intrinsic to the crystal lattice of biological apatite too [35], where their role is to
decrease the crystallite size [36] and increase the lattice strain [37] and solubility [38], thus
promoting the bone resorption process and speeding up its turnover and regeneration. The
content of carbonate ions in HAP used in this study is not supposed to be higher than 1 wt%
[39].
Largely accepted is both in vitro and in vivo growth of micro- and nano-particles of CAP via
aggregation of 1–2 nm sized growth units, a.k.a. Posner’s clusters [40 – 42]. One such basic
unit of growth was discerned in the course of the HR-TEM analysis of precipitated HAP
nanoparticles, possessing ~ 2 nm sized crystalline core abundant with twinned interfaces and
3 – 4 atomic layers thick and largely disordered surface (Fig. 1c). Aggregation of the
nanoparticles formed by coalescence of Posner’s singlets during the powder desiccation
process in vacuum into bigger, microsized blocks, two of which are shown in Fig. 1b,
presented the mechanism for the loading of the powders with the drug. Premature release of
the drug merely adsorbed on the nanoparticle surface is thus avoided and its retention within
the powder is enabled despite the immersion of the powder in the solvent for prolonged
periods of time [15]. Although developed independently from other groups, similar methods
for drug capture have been used earlier to ensure the extended release of vancomycin [43]
and aminoglycoside antibiotic, isepamacin sulfate [44] at a sustained rate from compacted
calcium phosphate powders. Although the loading method is different, using soaking rather
than desiccation-induced particle aggregation, PerOssal, a commercial mixture HAP and
calcium sulfate also relies on one such compaction of nanoparticles to ensure sustained
release of antibiotics [45]. Other methods for the fabrication of compact and mesoporous
blocks of HAP, without sintering at elevated pressures or temperatures at which the
degradation of encapsulated organics would have occurred, have also been reported [46 –
47].
Our previous studies on monocultures have confirmed the ability of CL-containing CAP
powders to inhibit the bacterial growth both on solid surfaces and in broths, regardless of the
CAP phase loaded with CL, with the minimal inhibitory concentrations ranging from 1 – 15
mg/ml of the particles. In this work, we have looked at the ability of the given antibiotic
powders to eradicate the same bacterium, S aureus, from infected osteoblastic cells, while
preserving their osteogenic potency.
As shown in Fig. 3a, following 2 h of co-culture, individual bacteria become visible inside
of the infected osteoblasts, while after 48 h of subsequent incubation of infected osteoblasts
with CL-containing HAP (Fig. 3d), ACP (Fig. 3e) and DCPA (Fig. 3f), the number of
bacteria visible both inside and outside of the cells becomes drastically reduced. In contrast,
the bacterial population in the untreated co-culture increased during the same time (Fig. 3c).
The cytoskeletal f-actin pattern in the untreated sample (Fig. 3c), however, revealed a
healthier, more striated and elongated appearance in comparison with the co-cultures treated
with the CL-containing nanoparticles (Fig. 3d–f). The release of cell debris, necrotic factors
and proteases following the antibiotic suppression of the pathogen thus obviously has a
negative effect on cell viability, whereas a state more akin to symbiotic homeostasis is
reached in untreated co-cultures, at least throughout the first 48 h following the infection. A
Uskoković and Desai Page 6
Mater Sci Eng C Mater Biol Appl. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
larger number of apoptotic cells, distinguishable by their clumped cytoskeletal
microfilaments (Fig. 3f) and extensive cell aggregation (Fig. 3e), is consequently found in
the treated samples after 48 of co-culture time.
Streaking of the osteoblastic cell lysates on agar plates has resulted in concordantly
decreased number of colonies or even reduced down to zero for HAP and ACP after 24 and
48 h of incubation, respectively (Fig. 4a–b). The fact that no colonies were visible on agars
despite the presence of a markedly lower amount of intracellular pathogens is explained by
the remnant antibiotic in the lysates, able to prevent the surface growth of the sufficiently
low concentration of the bacterium. BHI broths incubated for 4 h with fresh cell lysates
obtained after a 4 h incubation with different particles also exhibited markedly lower optical
densities measured at λ = 600 nm, directly proportional to the bacterial quantity, in
comparison with the positive control, invaded with the bacterium (Fig. 4c). This suggests a
significantly higher concentration of colony forming units in untreated co-cultured samples
compared to those treated with any of the antibiotic-containing nanoparticles or the pure
antibiotic. The same insight was derived from the measurements of fluorescence intensity of
the FITC-tagged bacterium per surface area of co-cultured samples, the results of which are
shown in Fig. 4d. As this intensity was significantly higher in the untreated samples, a
moderately effective inhibition of the bacterial growth by means of the antibiotic-containing
nanoparticles can be inferred, despite the negative effects on the osteoblastic cell viability
that the bacterial degradation process entailed. Interestingly, the concentration of the
fluorescent bacteria detected was higher in co-cultures treated with pure CL than in those
treated with CL-loaded CAPs (Fig. 4d), indicating greater antibiotic efficiency of CL
delivered by means of nanoparticulate CAP carriers compared to CL per se.
Previous studies have shown that S aureus harvested from the colonized osteoblasts that had
been treated with an antibiotic tends to become more resistant to the given therapy during
subsequent intracellular colonization [48]. Co-culture experiments carried out using S
aureus made potentially resistant to CL therapy showed similar intracellular invasion
efficiency after 2 h of infection (Fig. 5a). Their ability to eradicate the host cells was,
however, greater than for their regular counterparts. Namely, a few osteoblastic cells that
remained in the invaded culture uninhibited by the antibiotic-containing nanoparticles after
48 h were fully pervaded by the bacterium and in the final stage of necrosis (Fig. 5c). In
contrast, the concentration of S aureus colonies drastically dropped in co-cultures
supplemented with CAP/CL particles (Fig. 5d–f). A large portion of the cells, ~ 60 – 80 %,
however, underwent apoptosis during the treatment period. In view of the fact that actin
microfilaments play a role in the intracellular invasion of osteoblasts by S aureus [49], the
interrupted structure of f-actin, along with the formation of focal aggregates, visible in
invaded cells treated with HAP/CL (Fig. 5d) and ACP/CL (Fig. 5e) particles, is the natural
consequence of the infection and the subsequent bactericidal action. Due to its
comparatively low drug loading capacity and a greater acidity, DCPA has shown to be
nowhere as equally antibacterially effective as ACP and HAP (Fig. 5f).
Results of the tests used to determine the mitochondrial activity of differentiated MC3T3-E1
cells following the infection are shown in Fig. 6, indicating a higher metabolic activity of
cells in the presence of CAP/CL powders compared to those incubated either without any
antibiotics or with CL per se, including the negative, uninfected control, 24 h after the
infection. An insignificant decrease in viability of osteoblasts following infection and
antibacterial treatment suggests that despite the intracellular infection, no cell death initially
occurs as the bacteria, following a short reproductive period, enter a symbiotic balance with
the host cells and protect them from premature apoptosis. This finding is in agreement with
the previously observed protective effect on macrophages infected by S aureus against cell
death induced by the apoptotic initiator, staurosporine [50]. Byproducts of bacterial
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degradation in the presence of the antibiotic include necrotic factors and proteases, and even
though S aureus does not release endotoxins, as gram-negative bacteria do, this release may
explain why CL alone, uncoupled with the osteoconductive CAP drug carriers, leads to
lower metabolic activity compared to negative and positive controls after 24 h of incubation.
Seventy two hours after the infection, the mitochondrial activity of positive controls,
infected but not treated, becomes markedly higher compared to samples with reduced
bacterial population due to the antimicrobial effect of CL-containing HAP and ACP
powders. Increased respiration activity of cells has been reported earlier to result from their
infection [51 – 52]. This effect can be seen as a natural response of the cell directed to cope
with the deleterious effects caused by the pathogen [53]. Increased mitochondrial ATPase
activity is also observed to mark an early event during the infection-induced cell death [54].
Indeed, 24 h after the noticed increase in mitochondrial activity, the bacterial population
wiped out the osteoblasts. Decreasing the amount of the initially added colony forming units
fourfold delayed the peak in mitochondrial activity to 4–5 days after the infection and the
onset of full necrosis to 5–7 days following the invasion (data not shown). Osteoblasts
treated with the CL-containing nanoparticles likewise underwent necrosis after a sufficient
period of time.
Although necrotic and apoptotic effects of internalization of S aureus have been reported for
different cell types [55 – 59], observed was also homeostatic persistence of the bacterium
within vacuolar compartments inside of phagocytes [60] and adipocytes [61] for up to 5
days, the same time scale as that observed in our study, before the cells finally succumbed to
infection and died. Low levels of apoptosis leading to bacterial persistence in the course of
120 h after the infection were also observed in the case of epithelial HT-29 enterocytes [62].
This intracellular dormancy that S aureus is capable of presents its important virulence
strategy that assists in protecting the bacterium from antibiotics and host defense system and
provides a reservoir for chronic or systemic colonization of the organism. Treatment of the
infected cells even with a relatively high concentration of pure CL – 1 mg/ml – managed to
inhibit the bacterial growth, but not eliminate the source of infection. The large population
of intracellular bacteria still remained after 48 h, as evident from the number of colonies
formed upon plating them on agars (Fig. 4a–b). Frequent replenishment of the cell culture
media, however, led to weakening of the cell response to antibiotic therapy by means of CL,
which, like penicillin, has bacteriostatic rather than bactericidal potency, and after 3–5 days
of post-infection incubation with CL-containing particles, the bacteria began to multiply and
induce osteoblastic cell death. Research is under way as to how to extend the antibiotic
release within the therapeutic window that suppresses the growth of bacteria for longer
periods of time. The minimization of the bacterial presence inside of the infected cells with
the use of the antibiotic-loaded CAP particles is still promising in view of the fact that the
uncompromised immune system can eliminate a vast majority of even severe bacterial
infections for as long as the bacterial growth is somewhat suppressed by the therapeutic
means.
Internalized S aureus flocci after 2 h of infection were shown in Figs. 3a, while cells
displaying a markedly lesser concentration of the intracellular bacterial contaminants after 2
days of incubation with the antibiotic-containing CAP powders were shown in Fig. 3d–f. To
explain a higher antimicrobial potency of CL coupled to CAP rather than CL alone, optical
confocal imaging was performed on MC3T3-E1 fibroblasts incubated with the antibiotic-
loaded CAP powders. After 48 h of the incubation time, a large amount of CAP particles
was found within the cells (Fig. 7a–c), as indicated by the overlap of fluorescence signals
originating from CL-loaded CAP particles (green) and from intracellular structures, in this
case nucleus (blue) and cytoskeletal microfilaments (red). All the monophasic CAP
particles, from the most soluble DCPA to the least soluble HAP, irrespective of whether
they were loaded with CL or not, were able to penetrate the cell membrane. The hazier
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fluorescence derived from CAP particles in the case of DCPA suggests smaller and more
dispersed particles present inside of the cell, as opposed to HAP and ACP, which maintained
the form of larger aggregates. Nanoparticles of CAP and various other compositions are
known to be able to facilely permeate the cell membrane and localize themselves in the
intracellular environment [63]. Comparatively high transfection efficiency of CAP powders
is, in fact, the reason why CAPs have been one of the most affordable candidates for non-
viral gene delivery carriers [64 – 67] ever since they were first utilized for this purpose in
1973 [68]. The drug delivery efficacy is known to greatly depend on the physicochemical
nature of the carrier and reported was a 70-fold increase in the transfection efficacy of DNA
plasmids bound to polyethyleneimine-functionalized nanoscopic diamond particles able to
internalize themselves intracellularly [69]. A greater bioactivity of an anticancer therapeutic
was also found out to result from its delivery in the nanoparticle-bound form, along with a
reduced myelosuppression and, thus, toxicity of the treatment compared to therapies based
on applying the pure drug [70]. Longer intracellular retention times of the drug delivered by
means of a nanocarrier were also observed in the case of delivery of doxorubicin to cancer
cells using liposomes, leading to a 5000-fold enhancement of the therapeutic efficiency in
vitro [71]. It can be speculated that while the drug per se tends to be partially ejected from
the cell following its uptake, this effect is prone to happen to a much lesser extent when the
permeability of the cell becomes compromised by the penetration of the nanoparticles that,
in addition, prevent the drug excretion from occurring by keeping it bound to their surface.
The nanostructured nature of the particles is a vital factor in ensuring their excellent cell
permeation capabilities [72] as much as their aggregation is vital in preventing an overly fast
release of the adsorbed drug molecules. The bactericidal effect of CL is tied to its ability to
inhibit the bacterial protein synthesis by binding to ribosomal subunits [73]. As such, the
effectiveness of the antibiotic therapy by means of CL is conditioned by the cytoplasmic
penetration of CL released from the CAP particle surface as well as by the cellular
internalization of CL-containing nanosized CAP particles. The latter process does not take
place instantaneously and only after a few hours of incubation do the first intracellular
particles begin to be observed, as displayed in Fig. 7d.
While comparatively effectively eliminating both the extracellular and intracellular source
of bacterial infection, CAP particles loaded with CL have demonstrated high levels of
osteoconductivity, as evidenced by the morphology of osteoblastic cells adhering onto the
given particles. Their excellent spreading and intimate contact with the particles (Fig. 8a–c),
altogether with the healthy appearance of f-actin pattern (Fig. 8d), known to play a crucial
role in the internalization of S aureus by osteoblasts [74], serve as an evidence of this. Aside
from maximizing the specific surface area available for adsorption of the drug, the
nanoparticulate nature of CAP carriers interacting with the cells may be an important factor
in ensuring the high levels of observed osteoconductivity. Namely, increased osteoblast
adhesion has already been detected on compacts composed of nanoparticulate HAP
compared to those comprising microsized particles of the same chemical composition [75].
Furthermore, an inverse proportionality was observed between (a) the level of adherence and
proliferation of osteoblasts, and (b) the size of the nanoparticles (> 20 nm) comprising the
surface that the osteoblasts adhered to [76, 77].
CAP particles have been shown to exhibit toxic effects on cells at high concentrations [78]
due to release of Ca2+ ions that interfere with the ionic channel transport [79]. In our case,
this effect has not been observed at concentrations up to 20 mg/cm2. The example of toxic
effects of a carrier incorporated in CAP particles is shown in Fig. 9 in terms of the disrupted
f-actin network (Fig. 9a) and morphology (Fig. 9b) of osteoblastic cells in contact with
cobalt-doped (5 – 12 wt%) HAP particles. Whereas the osteoconductive HAP surface
promotes an evident spreading of osteoblasts on it, the release of cobalt ions incorporated in
the crystal lattice of HAP exerts a somewhat necrotic effect on the cells, which was also
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evidenced by a markedly lower mitochondrial activity: only 15 – 20 % of the control, as
compared to the approximately twice higher activity for CL-containing HAP particles with
respect to the control (Fig. 6), following an identical incubation time. Overall, favorable
material-cell interaction is the foundation of facile bioresorption and repair of the diseased
and demineralized hard tissue. Viable osteoblastic cells with healthy morphologies observed
in close contact with the antibiotic-loaded particles unequivocally suggest their moderate-to-
high levels of osteogenic potency.
Our gene expression analysis, the results of which are displayed in Fig. 10, has shown that
not only are the antibiotic-containing HAP particles able to partially reverse this trend and
minimize the presence of the pathogen, but they are also able to boost the expression of
mineralization markers. In our previous study, we showed that while CL per se induced
significant downregulation of osteogenic markers BGLAP, Col I and Runx2 in osteoblastic
cells, the gene expression induced by HAP loaded with CL was at the same level as in the
presence of pure HAP, significantly upregulated with respect to the control [20]. Here we
show similar downregulation of BGLAP and Runx2 in osteoblasts invaded with S aureus and
incubated with CL only. In contrast, cells incubated with HAP/CL demonstrate significant
upregulation of the given genes with respect to both the control and the cells incubated with
HAP or CL alone. Apparently, HAP/CL particles are able to compensate for the negative
effect of the pure drug on the expression of osteogenic markers and provide a favorable
synergy between antibacterial and osteogenic potencies of the composite biomaterial
designed for the treatment of bone infection.
The majority of mature bone extracellular matrix, ~ 90 % of it, is composed of collagenous
proteins, the most pervasive of which is collagen type I, while the rest of it is comprised of
noncollagenous proteins, the most abundant of which is osteocalcin (BGLAP), directly
involved in nucleation of apatite crystals [80]. Protocollagen type I (Col I), a metabolic
precursor for collagen type I, appeared to be downregulated for both the positive control,
infected but untreated, as well as for infected cells treated with HAP, CL, and HAP/CL (Fig.
10). The reason for this effect relates to the fact that, unlike BGLAP and Runx2 that are
specific for the differentiated MC3T3-E1 cells, Col I is expressed by non-differentiated
fibroblasts too and the infection process obviously reduces the ability of cells to produce this
vital ingredient of the extracellular matrix. Moreover, the two osteogenic markers BGLAP
and Runx2 were upregulated for the positive control, suggesting that the infection process
boosts the metabolic and osteogenic activity of cells to counteract the necrotic effects of the
bacterial invasion. Despite the fact that it has been shown that the infection of cultured
osteoblasts with S aureus leads to diminished proliferation, increased apoptosis and
inhibited mineralization [81], our results indicate that osteoblasts can coexist with the
opportunistic intracellular pathogen for days as well as that the infection entails an increase
in the expression of proteins involved in the mineralization process, a completely opposite
effect from that induced by the pure antibiotic. Still, however, the mRNA transcript level
corresponding to the expression of the housekeeping gene β-actin (ACTB) becomes
significantly diminished among the cell population that underwent invasion, even though the
antibiotic therapies, with and without the CAP particles as the drug carrier, lead to a partial
recovery of this unfavorable effect that indicates the ongoing loss of integrity of cytoskelatal
microfilaments due to the infection. Two more genes that encode for proteins playing roles
in bone formation, ALP and BSP-1, were also analyzed and whereas markedly lower
expressions of ALP were observed for co-cultured samples in comparison with the
uninfected control, the opposite effect was observed for BSP-1. Aside from expressing
osteopontin, an acidic phosphoprotein associated with (a) pathological and inhibited
mineralization [82], (b) acute and chronic inflammation [83], and (c) tumor invasiveness,
progression and metastasis [84, 85], BSP-1 is a negative regulator of proliferation and
differentiation in MC3T3-E1 cells [86], and its upregulation coincides with the gradual
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reduction in cell viability caused by the infection. Due to an array of mutually antagonistic
effects that ALP downregulation can suggest, the causes of its diminished expression are
more difficult to speculate about, except for the readily hypothesized ongoing reduction in
the cell viability that the infection process induces.
Summary
Staphylococcus aureus is the main causative agent of osteomyelitis, an infectious disease
that often entails postoperative bone tissue treatments and is on the rise due to the
continuously aging population. Earlier we have shown that calcium phosphates of various
stoichiometries could present a viable candidate for drug delivery carriers for tunable release
of antibiotics in the treatment of osteomyelitis [15, 20]. In this work we have extended our
assessment of the simultaneous osteogenic and antibacterial performance of antibiotic-
loaded calcium phosphate nanoparticles to co-cultures comprising osteoblastic cells infected
with Staphylococcus aureus. To that end, we have tested clindamycin-loaded calcium
phosphate nanoparticles of different monophasic compositions, including monetite,
amorphous calcium phosphate and hydroxyapatite. Internalization of the bacterium by the
osteoblasts has been evidenced to initially hinder their antibody- or neutrophil-mediated
destruction and forestall an effective antibiotic therapy by means of pure bacteriostatics. Our
results have demonstrated that clindamycin-loaded hydroxyapatite and amorphous calcium
phosphate particles appear to be more effective in decreasing the intracellular bacterial
population and slowing down the growth of the pathogen than the pure antibiotic.
Simultaneously, the osteoblastic cells were shown to engage in an intimate interface with the
microscopic compacts composed of nanosized calcium phosphate particles loaded with the
antibiotic, which is a strong sign of the osteoconductive nature of the material. Moreover,
the bone growth markers were upregulated in the presence of clindamycin-loaded
hydroxyapatite, illustrating the crucial effect of the osteogenic nature of the drug carrier in
facilitating revitalization of bone tissues subjected to necrosis due to infection. More
specifically, the upregulation of the expression of different bone growth markers, indicative
of the increased osteogenic activity of the osteoblastic cells, was larger in the presence of
calcium phosphate particles loaded with the antibiotic than in the case of (i) untreated
infection, (ii) infection treated with the antibiotic only, or (iii) infection treated with
antibiotic-free CAP particles. As in agreement with our previous studies, here we have
confirmed the ability of clindamycin-loaded calcium phosphate particles to compensate for
the negative effect of the pure drug on the expression of osteogenic markers and provide a
synergy between antibacterial and osteogenic potencies promising in the consideration of the
material as a clinical candidate. Namely, the simultaneous osteogenic and antimicrobial
performance of the material developed in this study, altogether with its ability to exhibit
sustained drug release profiles, may favor it as an alternative to prolonged antibiotic
administration and surgical debridement typically prescribed in the treatment of
osteomyelitis.
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Highlights
1. Calcium phosphate nanoparticles were loaded with clindamycin phosphate.
2. Efficacy of the particles was evaluated against osteoblasts infected with S
aureus.
3. Particles were internalized and minimized the amount of intracellular bacterium.
4. Cell necrosis was not prevented due to formation of toxic degradation
byproducts.
5. Particles upreguled the expression of osteogenic markers in infected osteoblasts.
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Fig. 1.
Scanning electron micrographs of spherical and monodisperse HAP nanoparticles (a),
forming compact microscopic blocks and capturing the adsorbed drug upon desiccation (b).
(c) A transmission electron micrograph of a single nanoscopic particle of HAP with denoted
defect-laden crystalline particle core and the largely amorphous, disorder surface atomic
layers thereof. DCPA (d) and ACP (e) powders display similar nanoparticle size and shape
characteristics.
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Fig. 2.
(a) XRD patterns of three different monophasic CAP nanopowders with different solubility
products (Ksp) utilized in this study: (a) DCPA (pKsp = 7); (b) ACP (pKsp = 20 – 25); (c)
HAP (pKsp = 114). (b) Raman spectrum of HAP in 900 – 1200 cm−1 region, showing three
bands originating from the symmetrical (ν1) and asymmetrical (ν3) stretches of the
phosphate ion and from the symmetrical stretch of the carbonate ion, at 961, 1048 and 1075
cm−1, respectively.
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Fig. 3.
Z-stacked confocal optical images of fluorescently stained osteoblastic cell nuclei (blue) and
cytoskeletal f-actin (red), invaded with S aureus (green): (a) positive control stained
immediately following the 2 h infection, showing intracellular presence of the bacterium; (b)
negative control at 48 h of incubation time; (c) positive control at 48 h of incubation time;
co-cultured samples incubated with 2 mg/cm2 of HAP/CL (d), ACP/CL (e), and DCPA/CL
(f) at 48 h of incubation time. The sizes of images are 270 × 270 μm (a, b), 450 × 450 μm (c,
d, f), and 350 × 350 μm (e).
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Fig. 4.
(a) Bacterial colonies forming on sheep blood agar plates following streaking of lysates of
cells invaded by S aureus and incubated with either no particles (control), or with CL-loaded
HAP (HAP), or pure CL (CL); (b) the number of bacterial colonies counted following
overnight incubation of streaked lysates of cells invaded by S aureus and incubated for
different times (1, 8, 24 h, and 5 days) with either no particles (C+), or with CL-loaded HAP
(HAP), CL-loaded ACP (ACP), CL-loaded DCPA (DCPA), or pure CL (CL); (c) optical
densities at λ = 600 nm for BHI broths incubated for 4 h with fresh cell lysates obtained
after a 4 h incubation with different particles; (d) average pixel intensity, directly relatable to
the bacterial number in co-cultured samples, measured at the excitation wavelength of 488
nm and the detection wavelength range of 520 – 550 nm. Data are shown as arithmetic
means with error bars representing standard deviation (* => p < 0.05 with respect to the C+
control group).
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Fig. 5.
Z-stacked confocal optical images of fluorescently stained osteoblastic cell nuclei (blue) and
cytoskeletal f-actin (red), invaded with S aureus (green) previously made potentially
resistant to CL therapy: (a) positive control stained immediately following the infection,
showing intracellular presence of the bacterium; (b) negative control at 48 h of incubation
time; (c) positive control at 48 h of incubation time; co-cultured samples incubated with 2
mg/cm2 of HAP/CL (d), ACP/CL (e), and DCPA/CL (f). The size of each image is 450 ×
450 μm.
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Fig. 6.
Mitochondrial activity indicative of cell viability after different treatment intervals (24 and
72 h), normalized to the negative control (C−) and determined by the MTT assay for
different types of CL-containing particles (HAP, ACP, DCPA), including CL alone and
positive control, infected but not subjected to the treatment with the CL-containing particles
(C+). Data normalized to the optical density at λ = 570 nm of the negative control are shown
as arithmetic means with error bars representing standard deviation (* => p < 0.05 with
respect to the C− control group).
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Fig. 7.
Single plane confocal optical images of fluorescently stained osteoblastic cell nucleus (blue)
and cytoskeletal f-actin (red), and CL-containing CAP particles (green) of different
monophasic compositions – HAP (a, d), ACP (b), and DCPA (c) – following 48 h (a) and 4
h (d) of incubation. The sizes of images are 270 × 270 μm.
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Fig. 8.
Single-plane confocal optical images of fluorescently stained HAP/CL, ACP/CL and DCPA/
CL particles (green) and osteoblastic MC3T3-E1 cells (f-actin - red; nucleus - blue)
following 21 days of incubation in the differentiation medium. The sizes of the images are
675 × 675 μm.
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Fig. 9.
Confocal optical micrographs of osteoblastic cells exhibiting disrupted cytoskeletal f-actin
pattern (red) following incubation with Co-doped HAP particles (green) (a) as well as
becoming morphologically deformed in contact with them (b). The sizes of the images are
270 × 270 μm.
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Fig. 10.
The comparative effect of pure HAP, pure CL and HAP loaded with CL (HAP/CL) on the
mRNA expression of the housekeeping gene ACTB and different osteogenic markers -
BGLAP, Runx2, BSP-1, ALP and Col I - in osteoblastic MC3T3-E1 cells infected with S
aureus for 2 h and then incubated for 24 h with HAP, CL or HAP/CL. mRNA expression
was detected by quantitative RT-polymerase chain reaction relative to the housekeeping
gene ACTB. Data normalized to the expression of ACTB are shown as arithmetic means with
error bars representing standard deviation. Genes significantly (p < 0.05) upregulated with
respect to the control group are marked with *. Genes significantly (p < 0.05) downregulated
with respect to the negative control group (C−) are marked with +.
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Table 2
Primer pair sequences used for the qPCR analysis.
Gene Forward 5′–3′ primer Reverse 5′–3′ primer
ACTB GGCCCAGAGCAAGAGAGGTATCC ACGCACGATTTCCCTCTCAGC
BSP-1 AGGAGGAGGCAGAGCACA CTGGTATGGCACAGGTGATG
BGLAP CTCACAGATGCCAAGCCCA CCAAGGTAGCGCCGGAGTCT
Col I GCGAAGGCAACAGTCGCT CTTGGTGGTTTTGTATTCGATGAC
Runx2 AAATGCCTCCGCTGTTATGAA GCTCCGGCCCACAAATCT
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